Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights


Por: Coll, R, Brey, N, Sturla, AL, Viñas, J, Arnan, M, Pomares, H, Vives, S, Balarí, AS, Sancho, JM and Gallardo, D

Publicada: 1 dic 2025 Ahead of Print: 1 dic 2025
Resumen:


Filiaciones:
Brey, N:
 Hosp Josep Trueta, Girona, Spain

Sturla, AL:
 Inst Catala Oncol Hospitalet, Idibell, Hospitalet, Spain

Viñas, J:
 Hosp Badalona Germans Trias & Pujol, Badalona, Spain

Arnan, M:
 Inst Catala Oncol Hospitalet, IDIBELL, Barcelona, Spain

Pomares, H:
 Inst Catala Oncol Hospitalet, IDIBELL, Barcelona, Spain

:
 Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

Balarí, AS:
 Hosp Josep Trueta, Inst Catala Oncol, Girona, Spain

 Inst Catala Oncol Hospitalet, IDIBELL, Barcelona, Spain

:
 Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

Gallardo, D:
 Inst Catala Oncol Girona, Girona, Spain
ISSN: 00064971





Blood
Editorial
American Society of Hematology, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 146 Número:
Páginas: 6896-6897
WOS Id: 001669517100046

MÉTRICAS